Tactile Systems Technology (TCMD)
Market Price (6/14/2026): $26.26 | Market Cap: $592.5 MilSector: Health Care | Industry: Life Sciences Tools & Services
Tactile Systems Technology (TCMD)
Market Price (6/14/2026): $26.26Market Cap: $592.5 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% Attractive yieldFCF Yield is 6.6% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, Aging Population & Chronic Disease, and Precision Medicine. Themes include Remote Patient Monitoring, Show more. | Weak multi-year price returns3Y Excs Rtn is -65% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10% | Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 29x Stock price has recently run up significantly12M Rtn12 month market price return is 167% Key risksTCMD key risks include [1] regulatory scrutiny and audits of its billing practices, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Attractive yieldFCF Yield is 6.6% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, Aging Population & Chronic Disease, and Precision Medicine. Themes include Remote Patient Monitoring, Show more. |
| Weak multi-year price returns3Y Excs Rtn is -65% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10% |
| Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 29x |
| Stock price has recently run up significantly12M Rtn12 month market price return is 167% |
| Key risksTCMD key risks include [1] regulatory scrutiny and audits of its billing practices, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Tactile Systems Technology (TCMD) stock has lost about 10% since 2/28/2026 because of the following key factors:
1. Introduction of new Medicare prior authorization requirement for pneumatic compression devices.
Tactile Systems Technology's stock experienced downward pressure following the announcement and implementation of a new Medicare prior authorization requirement for pneumatic compression devices, which became effective on April 13, 2026. This regulatory change was noted by management during the Q4 2025 earnings call as a factor that could lead to a "potential short-term impact" on the broader lymphedema market, increasing administrative steps and potentially slowing access to therapy.
2. Mixed financial results for fiscal Q1 2026.
While Tactile Systems Technology reported a 23% year-over-year increase in revenue to $75.3 million for fiscal Q1 2026, exceeding analyst expectations, the company simultaneously missed earnings per share (EPS) estimates. The reported net loss was $1.8 million, or -$0.08 per share, missing the consensus estimate of -$0.07 per share. This mixed performance, particularly the EPS miss, likely contributed to investor uncertainty regarding profitability despite top-line growth.
Show more
Stock Movement Drivers
Fundamental Drivers
The -10.2% change in TCMD stock from 2/28/2026 to 6/13/2026 was primarily driven by a -14.9% change in the company's P/E Multiple.| (LTM values as of) | 2282026 | 6132026 | Change |
|---|---|---|---|
| Stock Price ($) | 29.29 | 26.31 | -10.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 330 | 344 | 4.2% |
| Net Income Margin (%) | 5.8% | 5.9% | 2.0% |
| P/E Multiple | 34.4 | 29.2 | -14.9% |
| Shares Outstanding (Mil) | 22 | 23 | -0.8% |
| Cumulative Contribution | -10.2% |
Market Drivers
2/28/2026 to 6/13/2026| Return | Correlation | |
|---|---|---|
| TCMD | -10.2% | |
| Market (SPY) | 8.4% | 33.7% |
| Sector (XLV) | -3.6% | 41.5% |
Fundamental Drivers
The 2.3% change in TCMD stock from 11/30/2025 to 6/13/2026 was primarily driven by a 10.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 11302025 | 6132026 | Change |
|---|---|---|---|
| Stock Price ($) | 25.71 | 26.31 | 2.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 312 | 344 | 10.3% |
| Net Income Margin (%) | 5.8% | 5.9% | 1.3% |
| P/E Multiple | 31.6 | 29.2 | -7.4% |
| Shares Outstanding (Mil) | 22 | 23 | -1.1% |
| Cumulative Contribution | 2.3% |
Market Drivers
11/30/2025 to 6/13/2026| Return | Correlation | |
|---|---|---|
| TCMD | 2.3% | |
| Market (SPY) | 9.2% | 28.2% |
| Sector (XLV) | -1.6% | 20.1% |
Fundamental Drivers
The 166.3% change in TCMD stock from 5/31/2025 to 6/13/2026 was primarily driven by a 102.2% change in the company's P/E Multiple.| (LTM values as of) | 5312025 | 6132026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.88 | 26.31 | 166.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 293 | 344 | 17.2% |
| Net Income Margin (%) | 5.5% | 5.9% | 7.0% |
| P/E Multiple | 14.5 | 29.2 | 102.2% |
| Shares Outstanding (Mil) | 24 | 23 | 5.1% |
| Cumulative Contribution | 166.3% |
Market Drivers
5/31/2025 to 6/13/2026| Return | Correlation | |
|---|---|---|
| TCMD | 166.3% | |
| Market (SPY) | 27.3% | 12.7% |
| Sector (XLV) | 18.0% | 20.6% |
Fundamental Drivers
The 25.2% change in TCMD stock from 5/31/2023 to 6/13/2026 was primarily driven by a 33.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 5312023 | 6132026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.02 | 26.31 | 25.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 258 | 344 | 33.3% |
| P/S Multiple | 1.7 | 1.7 | -0.5% |
| Shares Outstanding (Mil) | 21 | 23 | -5.7% |
| Cumulative Contribution | 25.2% |
Market Drivers
5/31/2023 to 6/13/2026| Return | Correlation | |
|---|---|---|
| TCMD | 25.2% | |
| Market (SPY) | 84.5% | 22.6% |
| Sector (XLV) | 26.5% | 24.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TCMD Return | -58% | -40% | 25% | 20% | 69% | -9% | -41% |
| Peers Return | 12% | -16% | 12% | 23% | -30% | 27% | 15% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| TCMD Win Rate | 25% | 42% | 67% | 58% | 67% | 50% | |
| Peers Win Rate | 55% | 42% | 53% | 50% | 37% | 57% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| TCMD Max Drawdown | -70% | -70% | -61% | -34% | -48% | -32% | |
| Peers Max Drawdown | -25% | -42% | -34% | -32% | -48% | -21% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ELMD, ENOV, ITGR, AVNS, CNMD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/12/2026 (YTD)
How Low Can It Go
| Event | TCMD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -39.2% | -18.8% |
| % Gain to Breakeven | 64.4% | 23.1% |
| Time to Breakeven | 164 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -56.7% | -9.5% |
| % Gain to Breakeven | 131.1% | 10.5% |
| Time to Breakeven | 729 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -66.8% | -24.5% |
| % Gain to Breakeven | 201.2% | 32.4% |
| Time to Breakeven | 330 days | 427 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -36.1% | -19.2% |
| % Gain to Breakeven | 56.5% | 23.8% |
| Time to Breakeven | 31 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -22.6% | -3.7% |
| % Gain to Breakeven | 29.1% | 3.9% |
| Time to Breakeven | 32 days | 6 days |
In The Past
Tactile Systems Technology's stock fell -39.2% during the 2025 US Tariff Shock. Such a loss loss requires a 64.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | TCMD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -39.2% | -18.8% |
| % Gain to Breakeven | 64.4% | 23.1% |
| Time to Breakeven | 164 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -56.7% | -9.5% |
| % Gain to Breakeven | 131.1% | 10.5% |
| Time to Breakeven | 729 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -66.8% | -24.5% |
| % Gain to Breakeven | 201.2% | 32.4% |
| Time to Breakeven | 330 days | 427 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -36.1% | -19.2% |
| % Gain to Breakeven | 56.5% | 23.8% |
| Time to Breakeven | 31 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -22.6% | -3.7% |
| % Gain to Breakeven | 29.1% | 3.9% |
| Time to Breakeven | 32 days | 6 days |
In The Past
Tactile Systems Technology's stock fell -39.2% during the 2025 US Tariff Shock. Such a loss loss requires a 64.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Tactile Systems Technology (TCMD)
AI Analysis | Feedback
ResMed for lymphedema and other chronic respiratory conditions.
A Medtronic focused on non-invasive, at-home devices for chronic diseases.
AI Analysis | Feedback
```html- Flexitouch Plus system: A pneumatic compression device for the treatment of lymphedema.
- Entre system: A portable pneumatic compression device for at-home treatment of venous disorders like lymphedema and chronic venous insufficiency.
- AffloVest: A portable high frequency chest wall oscillation vest for treating retained pulmonary secretions.
AI Analysis | Feedback
Tactile Systems Technology (TCMD) primarily sells its medical devices to individuals who suffer from specific chronic diseases. The company's customer base can be categorized as follows:
- Patients with Lymphedema: Individuals diagnosed with lymphedema who utilize the Flexitouch Plus system or Entre system for pneumatic compression therapy.
- Patients with Venous Disorders: Individuals with venous disorders, such as chronic venous insufficiency or venous leg ulcers, who use the Entre system for at-home treatment.
- Patients with Retained Pulmonary Secretions: Individuals suffering from conditions like bronchiectasis, cystic fibrosis, or various neuromuscular disorders, who require the AffloVest for high-frequency chest wall oscillation therapy to clear pulmonary secretions.
AI Analysis | Feedback
nullAI Analysis | Feedback
Sheri L. Dodd, Chief Executive Officer
Sheri L. Dodd joined Tactile Medical as Chief Executive Officer in July 2024 and has been a member of the board since 2021. Most recently, she served as President of Medtronic Canada at Medtronic plc, where she was responsible for all commercial activities for the sale and distribution of the Medtronic portfolio in Canada. During her 14 years at Medtronic, she held various functional vice president positions, including healthcare economics and market access, clinical research, health economics and policy, and general management roles for non-intensive diabetes therapies and telehealth. Prior to Medtronic, Ms. Dodd held various positions with Johnson & Johnson from 1997 to 2010, including Vice President of Health Economics and Reimbursement for Ethicon, Inc. She also served as an outcomes researcher with Orthopedic Surgeons, plc and as a project manager with the World Health Organization. Ms. Dodd holds a Bachelor of Science from the College of Idaho and a Master of Science in Health Planning and Financing from the London School of Economics and London School of Hygiene and Tropical Medicine.
Elaine M. Birkemeyer, Chief Financial Officer
Elaine M. Birkemeyer was appointed Chief Financial Officer of Tactile Medical effective March 20, 2023. She joined Tactile Medical from UnitedHealth Group Inc., where she held several senior leadership positions. Her roles at UnitedHealth Group included heading finance for its Optum Operations business as Vice President and Senior Vice President, serving as Chief Financial Officer of Rally Health (a digital health company wholly owned by UnitedHealth Group) starting in 2020, and most recently as Chief Financial Officer of UnitedHealth's Care Solutions portfolio. Earlier in her career, Ms. Birkemeyer served as Senior Finance Manager for Sleep Number Corporation and held various roles of increasing responsibility at Target Corporation, culminating in Senior Manager of Merchandise Finance for Target Sourcing Services.
Antonios P. Gasparis, MD, FACS, Chief Medical Officer
Dr. Antonios P. Gasparis serves as the Chief Medical Officer of Tactile Medical. He is a Professor of Surgery and Director of the Center for Vein Care at Stony Brook University. Dr. Gasparis is also a Past President of the American Venous Forum.
J. David Kaercher, Chief Information Officer
J. David Kaercher is the Chief Information Officer at Tactile Medical. His previous leadership roles include serving as CIO/CTO for multiple Blue Cross and Blue Shield plans. He also held positions such as Senior Vice President at US Bank Technology and Operations Services (TOS), Vice President at Allianz Life Technology, Director at Best Buy Technology, and Manager/Consultant at IBM. Mr. Kaercher is also a Veteran, having served as a US Army Infantry Officer.
AI Analysis | Feedback
Here are the key risks to Tactile Systems Technology (TCMD):
- Reimbursement and Regulatory Changes: Tactile Systems Technology faces significant risks from evolving healthcare regulations and reimbursement policies, particularly changes in Medicare prior-authorization rules, which could hinder its ability to secure payment from third-party payers for its medical devices. A historical Medicare audit from 2020, which resulted in a 71% denial rate for the company's submitted claims due to failure to establish medical necessity, underscores the sensitivity of its business model to these policies.
- Intense Competition and Technological Disruption: The company operates in a dynamic and competitive market for pneumatic compression therapy, facing challenges from existing players and new entrants. The emergence of alternative technologies, such as Koya Medical's non-pneumatic, shape-memory alloy-based compression system, presents a risk of technological obsolescence and could impact Tactile Systems Technology's market share and product differentiation.
- Legal and Compliance Challenges: Tactile Systems Technology is exposed to risks associated with ongoing legal matters and compliance issues, including an unresolved qui tam matter. Previous accusations from 2020, including overstating its total addressable market and engaging in a "daisy-chaining" scheme that allegedly led to rampant overprescribing and unfavorable Medicare audits, highlight potential vulnerabilities to legal scrutiny and reputational damage.
AI Analysis | Feedback
null
AI Analysis | Feedback
Tactile Systems Technology (TCMD) develops and provides medical devices for chronic diseases, primarily focusing on lymphedema, venous disorders, and retained pulmonary secretions. The addressable markets for their main products are substantial, predominantly within the United States.
Lymphedema (Flexitouch Plus system, Entre system)
The company's Flexitouch and Entre systems address the lymphedema market. The addressable market opportunity for Tactile Systems Technology's Flexitouch system in the United States is estimated to exceed $4.2 billion. For head and neck lymphedema specifically, the market opportunity in the United States is approximately $1 billion.
More broadly, the U.S. lymphedema treatment market size was valued at approximately US$ 5,185.98 million in 2022 and is projected to grow to US$ 8,320.07 million by 2028. Globally, the lymphedema treatment market was valued at USD 941.85 million in 2024 and is expected to reach USD 2,131.62 million by 2033. North America held the largest share of the global lymphedema treatment market in 2021.
Venous Disorders, including Chronic Venous Insufficiency (Entre system, Flexitouch Plus system)
The Entre system, along with the Flexitouch Plus system, is used for the at-home treatment of venous disorders such as chronic venous insufficiency (CVI). In the United States, more than 25 million people suffer from CVI. The total market size in the U.S. for Chronic Venous Insufficiency was estimated to be nearly USD 1,200 million in 2023.
Globally, the market for Chronic Venous Insufficiency (CVI) treatment was estimated at $15 billion in 2025 and is projected to reach $25 billion by 2033. North America is expected to be a dominant region in the CVI market.
Retained Pulmonary Secretions (AffloVest)
The AffloVest is designed for the treatment of retained pulmonary secretions, including conditions like bronchiectasis. The combined addressable market for lymphedema and bronchiectasis is stated as $10 billion.
Focusing on bronchiectasis, the global non-cystic fibrosis bronchiectasis treatment market size was valued at US$ 1.9 billion in 2024 and is projected to reach US$ 3.5 billion by 2035. North America held the largest revenue share of 41.7% in this market in 2024. The U.S. bronchiectasis market captured 47.4% of the revenue share within North America in 2024.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Tactile Systems Technology (TCMD) over the next 2-3 years:
- Continued Growth in Lymphedema Product Line: The company's Flexitouch Plus system, a leading pneumatic compression device for lymphedema, is expected to continue driving revenue growth. This is supported by strong commercial momentum, with the lymphedema business growing 16% year-over-year in Q4 2025. Updated Medicare National Coverage Determination (NCD) criteria are also providing a tailwind by allowing certain patients more direct access to the Flexitouch system.
- Expansion of Airway Clearance Product Line: The AffloVest, used for treating retained pulmonary secretions, is a significant growth driver. The airway clearance product line demonstrated substantial growth, surging 66% year-over-year in Q4 2025 and 52% for the full year 2025. This growth is attributed to increased awareness of bronchiectasis and strong partnerships with respiratory Durable Medical Equipment (DME) providers. AffloVest is positioned as the fastest-growing segment and is actively gaining market share.
- Strategic Acquisition of LymphaTech: The recent acquisition of LymphaTech is anticipated to enhance Tactile Systems' lymphedema solutions portfolio. By integrating LymphaTech's 3D digital measurement platform, Tactile aims to improve patient surveillance and streamline the path to therapy, particularly targeting the large population of undiagnosed lymphedema patients. This acquisition supports the company's evolution into a comprehensive integrated lymphedema solutions leader.
- Sales Force Expansion and Productivity Improvements: Investments made in 2024 in a new Customer Relationship Management (CRM) system and an expanded sales headcount are now translating into productivity gains. This enhanced sales capacity and improved sales representative productivity are expected to contribute to continued commercial momentum.
- Technological Investments and Operational Efficiencies: Tactile Systems is focusing on technological advancements, including the implementation of AI-enabled technology to enhance order processing speed, accuracy, and efficiency. These investments, along with a focus on improving operational efficiencies, have contributed to gross margin expansion and are expected to support future growth by streamlining business processes and improving the overall customer experience.
AI Analysis | Feedback
Share Repurchases
- In 2025, Tactile Systems Technology repurchased $26.561 million of its common stock.
- In 2024, the company made $3.508 million in payments for common stock repurchases.
- A new share repurchase program of up to $25 million was authorized in the third quarter of 2025.
Share Issuance
- In 2025, total proceeds from the exercise of common stock options and the issuance of common stock from the employee stock purchase plan amounted to approximately $1.614 million ($0.222 million from options and $1.392 million from the employee stock purchase plan).
- In 2024, total proceeds from the exercise of common stock options and the issuance of common stock from the employee stock purchase plan were approximately $1.684 million ($0.024 million from options and $1.660 million from the employee stock purchase plan).
- Stock-based compensation was $1.766 million for the nine months ended September 30, 2023, and $5.597 million for the year ended December 31, 2022.
Outbound Investments
- On September 8, 2021, Tactile Systems Technology acquired the assets of the AffloVest airway clearance product line.
Capital Expenditures
- The company generally operates with low capital expenditure requirements.
- Purchases of property, plant and equipment amounted to $0.5 million in the fourth quarter of 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Tactile Systems Technology Earnings Notes | 12/16/2025 | |
| Tactile Systems Technology Stock Jump Looks Great, But How Secure Is That Gain? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 30.54 |
| Mkt Cap | 1.1 |
| Rev LTM | 1,043 |
| Op Inc LTM | 33 |
| FCF LTM | 38 |
| FCF 3Y Avg | 41 |
| CFO LTM | 92 |
| CFO 3Y Avg | 114 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.1% |
| Rev Chg 3Y Avg | 10.1% |
| Rev Chg Q | 7.1% |
| QoQ Delta Rev Chg LTM | 1.7% |
| Op Inc Chg LTM | 20.9% |
| Op Inc Chg 3Y Avg | 37.6% |
| Op Mgn LTM | 8.8% |
| Op Mgn 3Y Avg | 9.3% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 10.5% |
| CFO/Rev 3Y Avg | 11.9% |
| FCF/Rev LTM | 7.2% |
| FCF/Rev 3Y Avg | 8.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.1 |
| P/S | 1.7 |
| P/Op Inc | 20.8 |
| P/EBIT | 13.0 |
| P/E | 20.7 |
| P/CFO | 15.3 |
| Total Yield | 3.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 5.7% |
| D/E | 0.3 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.2% |
| 3M Rtn | 3.7% |
| 6M Rtn | 9.5% |
| 12M Rtn | 31.0% |
| 3Y Rtn | 2.1% |
| 1M Excs Rtn | 1.5% |
| 3M Excs Rtn | -8.4% |
| 6M Excs Rtn | 1.0% |
| 12M Excs Rtn | 7.1% |
| 3Y Excs Rtn | -71.4% |
Price Behavior
| Market Price | $26.31 | |
| Market Cap ($ Bil) | 0.6 | |
| First Trading Date | 07/28/2016 | |
| Distance from 52W High | -20.4% | |
| 50 Days | 200 Days | |
| DMA Price | $24.57 | $23.71 |
| DMA Trend | up | down |
| Distance from DMA | 7.1% | 10.9% |
| 3M | 1YR | |
| Volatility | 41.4% | 66.1% |
| Downside Capture | 88.77 | 19.39 |
| Upside Capture | 44.65 | 131.58 |
| Correlation (SPY) | 32.7% | 12.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.25 | 1.71 | 1.13 | 1.25 | 0.72 | 0.86 |
| Up Beta | 6.19 | 3.01 | 1.87 | 1.38 | 1.09 | 0.84 |
| Down Beta | 1.43 | 0.21 | 0.43 | 0.70 | 0.04 | 0.63 |
| Up Capture | 28% | 24% | 38% | 118% | 163% | 76% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 10 | 18 | 28 | 56 | 124 | 364 |
| Down Capture | -163% | 232% | 159% | 150% | 48% | 103% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 10 | 23 | 34 | 67 | 122 | 375 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TCMD | |
|---|---|---|---|---|
| TCMD | 170.2% | 65.9% | 1.75 | - |
| Sector ETF (XLV) | 15.4% | 15.0% | 0.74 | 20.6% |
| Equity (SPY) | 24.9% | 12.3% | 1.52 | 12.2% |
| Gold (GLD) | 25.5% | 27.4% | 0.81 | 2.9% |
| Commodities (DBC) | 30.1% | 19.0% | 1.25 | -15.0% |
| Real Estate (VNQ) | 13.5% | 13.5% | 0.69 | 21.1% |
| Bitcoin (BTCUSD) | -41.7% | 42.2% | -1.16 | 3.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TCMD | |
|---|---|---|---|---|
| TCMD | -11.8% | 60.4% | 0.03 | - |
| Sector ETF (XLV) | 6.4% | 14.8% | 0.25 | 27.7% |
| Equity (SPY) | 13.5% | 17.1% | 0.61 | 29.9% |
| Gold (GLD) | 16.8% | 18.2% | 0.75 | 2.4% |
| Commodities (DBC) | 8.4% | 19.4% | 0.33 | -1.9% |
| Real Estate (VNQ) | 2.8% | 18.8% | 0.05 | 29.1% |
| Bitcoin (BTCUSD) | 13.6% | 54.4% | 0.44 | 13.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TCMD | |
|---|---|---|---|---|
| TCMD | 9.3% | 56.6% | 0.39 | - |
| Sector ETF (XLV) | 9.7% | 16.6% | 0.47 | 31.0% |
| Equity (SPY) | 15.3% | 17.9% | 0.73 | 33.3% |
| Gold (GLD) | 12.5% | 16.1% | 0.64 | 1.8% |
| Commodities (DBC) | 6.7% | 18.0% | 0.29 | 5.5% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.24 | 29.3% |
| Bitcoin (BTCUSD) | 60.3% | 66.8% | 1.00 | 8.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/5/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/4/2026 | 7.2% | 6.6% | 8.6% |
| 2/17/2026 | 17.8% | 2.1% | -3.6% |
| 11/3/2025 | 40.6% | 57.8% | 70.0% |
| 8/4/2025 | 26.8% | 23.1% | 33.9% |
| 5/5/2025 | -29.0% | -30.3% | -27.3% |
| 2/18/2025 | -13.3% | -18.1% | -22.8% |
| 11/4/2024 | -11.1% | 5.6% | 25.9% |
| 8/5/2024 | 13.9% | 12.4% | 15.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 13 | 13 |
| # Negative | 13 | 11 | 11 |
| Median Positive | 14.1% | 7.7% | 15.2% |
| Median Negative | -11.1% | -12.1% | -14.2% |
| Max Positive | 40.6% | 57.8% | 70.0% |
| Max Negative | -29.0% | -33.1% | -45.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/04/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-K |
| 09/30/2025 | 11/03/2025 | 10-Q |
| 06/30/2025 | 08/04/2025 | 10-Q |
| 03/31/2025 | 05/05/2025 | 10-Q |
| 12/31/2024 | 02/18/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/06/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 02/21/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/01/2022 | 10-Q |
Recent Forward Guidance
Updated 6/1/2026Latest: Q1 2026 Earnings Reported 5/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 360.00 Mil | 364.00 Mil | 368.00 Mil | 0.8% | Raised | Guidance: 361.00 Mil for 2026 | |
| 2026 Revenue Growth | 9.0% | 10.5% | 12.0% | 10.5% | 1.0% | Raised | Guidance: 9.5% for 2026 |
| 2026 Adjusted EBITDA | 49.00 Mil | 50.00 Mil | 51.00 Mil | 0 | Affirmed | Guidance: 50.00 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 2/17/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 357.00 Mil | 361.00 Mil | 365.00 Mil | 13.2% | Higher New | Actual: 319.00 Mil for 2025 | |
| 2026 Revenue Growth | 8.0% | 9.5% | 11.0% | 5.6% | 0.5% | Higher New | Actual: 9.0% for 2025 |
| 2026 Adjusted EBITDA | 49.00 Mil | 50.00 Mil | 51.00 Mil | 29.0% | Higher New | Actual: 38.75 Mil for 2025 | |
Insider Activity
Updated 5/13/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Birkemeyer, Elaine M | CHIEF FINANCIAL OFFICER | Direct | Sell | 5132026 | 24.49 | 4,631 | 113,404 | 3,188,044 | Form |
| 2 | Dodd, Sheri Louise | Chief Executive Officer | Direct | Sell | 2262026 | 28.94 | 10,993 | 318,144 | 7,058,178 | Form |
| 3 | Birkemeyer, Elaine M | CHIEF FINANCIAL OFFICER | Direct | Sell | 2262026 | 28.94 | 7,701 | 222,880 | 3,901,891 | Form |
| 4 | Burns, Kristie | Sr. VP Mktg & Clinical Affairs | Direct | Sell | 2262026 | 28.94 | 6,246 | 180,764 | 2,389,960 | Form |
| 5 | Birkemeyer, Elaine M | CHIEF FINANCIAL OFFICER | Direct | Sell | 2242026 | 28.30 | 5,518 | 156,144 | 4,032,908 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.